Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Conditions: Hematologic Malignancy; GvHD; GVHD,Acute; GVHD, Chronic; Hematopoietic Stem Cell Transplant; Acute Lymphoblastic Leukemia, Adult B-Cell; Acute Lymphoblastic Leukemia, Adult T-Cell; Acute Myeloid Leukemia in Remission; Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia, in Remission; Cancer Remission

Interventions: Biological: TRX103

Sponsors: Tr1X, Inc.

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 18, 2024Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments